The aim of the present article is to provide an up-to-date review on (i) the pathogenesis of the CRMO, (ii) the cutaneous manifestations associated to this rare disease and (iii) discuss the reported cases of drug-induced PG due to TNF-α inhibitors. Here, TNF is linked to chronic recurrent multifocal osteomyelitis.